Social media

Latest issue out now. If you, like our thousands of subscribers, would like a convenient way to keep on top of the latest regulatory authority updates, sign up to our free newsletter today. Compiled and collated by ICON...

A proactive approach to vaccine long-term follow-up planning enhances data quality and supports evolving regulatory and public expectations for robust safety and effectiveness evidence. ICON’s Dinah Knotts and Ted Wright...

Obesity trials are evolving, and weight alone is no longer enough. Join our live webinar to explore how the complementary tools of COAs + DHTs can deliver richer patient insights, enhancing obesity clinical trials. 📅 O...

Transforming partnerships through flexibility and focus. ​ Discover how ICON helped a sponsor transition to a blended model—combining FSO, FSP and standalone services for greater control and efficiency. https://ow.ly/y3...

Antibody-Drug Conjugates (ADCs) combine potent cytotoxins with selective antibodies for targeted cancer therapy—but their complexity presents major challenges in pharmacokinetics (PK) and bioanalysis. In our latest artic...

ICON is delighted to continue its partnership with the Outsourcing in Clinical Trials Southern California conference taking place 23 – 24 September at the Hyatt Regency La Jolla at Aventine, San Diego, CA. Join us at b...

ICON will be on site at #DPHARM2025, 16–17 September at the Loews Philadelphia Hotel, where the focus is on transforming clinical research through disruptive innovation. Meet our team at booth #305 to discuss how ICON’s ...

The volume of life sciences research is growing fast - making it harder than ever to find reliable insights. Our new whitepaper shows you how to use systematic literature reviews (SLRs) to generate high-quality evidence ...

Agencies like the FDA and EMA are more receptive to submissions integrating evidence across indications, lowering barriers for label expansion. But what commercialisation strategies are most successful following regul...

The therapeutic landscape for obesity is changing rapidly. Endpoints focused only on weight loss are no longer enough. Regulators now expect measures that capture the entire patient experience. Join ICON experts on Oct...

Biomarkers aren’t just supporting drug development, they’re driving it. This expert-led report produced in conjunction with Drug Target Review explores how biomarker science is advancing trial design, accelerating clinic...

Customised collaboration -- Discover how we helped sponsors transition to blended models, drive efficiency and create impactful outcomes. Learn more across a range of real-world case studies. Explore the outcomes here: ...